TABLE 1.
Number of Relapses Avoided per Patient over Respective Horizons for Models 1 and 2
| Model 1: PEG | |||||
|---|---|---|---|---|---|
| DMT | Number of Relapses (Placebo) | Number of Patients (Placebo) | Relative Relapse Rate Reduction (%) | Number of Relapses Avoided per Patient | Number of Relapses per Patient |
| PEG5 | 0.40 | 500 | 36 | 0.20 | 0.35 |
| IM IFN beta-1a17 | 0.82 | 143 | 18 | 0.10 | 0.45 |
| SC IFN beta-1b18 | 1.27 | 123 | 34 | 0.19 | 0.36 |
| GA19 | 0.84 | 126 | 29 | 0.16 | 0.39 |
| FIN20 | 0.40 | 418 | 54 | 0.30 | 0.25 |
| NAT21 | 0.73 | 315 | 65 | 0.36 | 0.19 |
| DMF22 | 0.36 | 408 | 53 | 0.29 | 0.26 |
| Model 2: ALT | |||||
| DMT | Number of Relapses at Baseline | Number of Patients | Number of Relapses at 2 Years | Relative Relapse Rate Reduction (%) | Number of Relapses Avoided per Patient |
| ALT6 | 1.7 | 426 | 0.52 | 69.41 | 1.18 |
| IFN beta-1a 44 μg23 | 1.5 | 202 | 1.04 | 30.67 | 0.46 |
ALT = alemtuzumab; DMF = dimethyl fumarate; DMT = disease-modifying therapy; FIN = fingolimod; GA = glatiramer acetate; IFN = interferon; IM = intramuscular; NAT = natalizumab; PEG = peginterferon beta-1a; SC = subcutaneous.